Tomaki M, Ichinose M, Miura M, Hirayama Y, Yamauchi H, Nakajima N, Shirato K
July 31 Product: Johnson & Johnsons Darzalex Faspro Indication : Multiple myeloma Johnson & Johnson picked up another indication for its Darzalex Faspro Wednesday as the FDA approved the therapy, in combination with bortezomib, lenalidomide and dexamethasone, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant
Glutathione supplements are generally safe for daily use when taken as recommended
Small molecules targeting ferroptosis by regulating the SLC7A11/GPX4 pathway The SLC7A11/GPX4 axis is vital in preventing cellular ferroptosis
Our goal is to offer safe, evidence-informed care while ensuring each patient fully understands their options before beginning any treatment
Optional 4 week break after week 12, then resume at maintenance dosing